Madrigal Secures Exclusive Global License for Aro-Pnpla3 from Arrowhead, Committing Up to $1 Billion in Milestones
MDGL sits 95% above its 52-week low of $265.
Summary
Madrigal Pharmaceuticals announced an exclusive global licensing agreement for Aro-Pnpla3 from Arrowhead. The deal involves a $25 million upfront payment to Arrowhead, with potential milestone payments totaling up to $975 million, in addition to royalties. This agreement strategically expands Madrigal's development pipeline, aligning with the company's stated goal in its recent 10-K to expand its MASH pipeline through new licensing agreements. While the upfront cost is relatively modest, the potential $975 million in milestones represents a significant long-term investment in a new asset. Traders will be watching for further updates on the clinical development of Aro-Pnpla3 and any future financial implications.
At the time of this announcement, MDGL was trading at $517.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.9B. The 52-week trading range was $265.00 to $615.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.